294 related articles for article (PubMed ID: 9062121)
21. Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast.
Elsea SH; Osheroff N; Nitiss JL
J Biol Chem; 1992 Jul; 267(19):13150-3. PubMed ID: 1320012
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and antitumour activities of tetracyclic quinolone antineoplastic agents.
Chu DT; Hallas R; Tanaka SK; Alder J; Balli D; Plattner JJ
Drugs Exp Clin Res; 1994; 20(5):177-83. PubMed ID: 7875053
[TBL] [Abstract][Full Text] [Related]
23. Mediation of multi-drug resistance in a Chinese hamster ovary cell line by a mutant type II topoisomerase.
Glisson BS; Sullivan DM; Gupta R; Ross WE
NCI Monogr; 1987; (4):89-93. PubMed ID: 2819738
[TBL] [Abstract][Full Text] [Related]
24. Effect of retinoic acid on DNA cleavage and cytotoxicity of topoisomerase II-reactive drugs in a human head and neck squamous carcinoma cell line.
Kim HK; Zwelling LA; Sacks PG; Hong WK; Chan D; Silberman L; Glisson BS
Cancer Res; 1989 Mar; 49(5):1197-201. PubMed ID: 2537145
[TBL] [Abstract][Full Text] [Related]
25. Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II.
Robinson MJ; Osheroff N
Biochemistry; 1991 Feb; 30(7):1807-13. PubMed ID: 1847075
[TBL] [Abstract][Full Text] [Related]
26. A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors.
Hsiung Y; Elsea SH; Osheroff N; Nitiss JL
J Biol Chem; 1995 Sep; 270(35):20359-64. PubMed ID: 7657608
[TBL] [Abstract][Full Text] [Related]
27. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene.
Pommier Y; Orr A; Kohn KW; Riou JF
Cancer Res; 1992 Jun; 52(11):3125-30. PubMed ID: 1317259
[TBL] [Abstract][Full Text] [Related]
28. Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.
Nitiss JL; Vilalta PM; Wu H; McMahon J
Mol Pharmacol; 1994 Oct; 46(4):773-7. PubMed ID: 7969059
[TBL] [Abstract][Full Text] [Related]
29. DNA topoisomerase II as the primary target of anti-tumor anthracyclines.
Zunino F; Capranico G
Anticancer Drug Des; 1990 Nov; 5(4):307-17. PubMed ID: 1963303
[TBL] [Abstract][Full Text] [Related]
30. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.
Liu YX; Hsiung Y; Jannatipour M; Yeh Y; Nitiss JL
Cancer Res; 1994 Jun; 54(11):2943-51. PubMed ID: 8187080
[TBL] [Abstract][Full Text] [Related]
31. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors.
Nitiss JL; Liu YX; Hsiung Y
Cancer Res; 1993 Jan; 53(1):89-93. PubMed ID: 8380128
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the effects of genistein and amsacrine on leukemia cell proliferation.
Finlay GJ; Holdaway KM; Baguley BC
Oncol Res; 1994; 6(1):33-7. PubMed ID: 7919550
[TBL] [Abstract][Full Text] [Related]
33. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note.
Kaufmann SH
Cancer Res; 1989 Nov; 49(21):5870-8. PubMed ID: 2790800
[TBL] [Abstract][Full Text] [Related]
34. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II.
Rowe TC; Chen GL; Hsiang YH; Liu LF
Cancer Res; 1986 Apr; 46(4 Pt 2):2021-6. PubMed ID: 3004716
[TBL] [Abstract][Full Text] [Related]
35. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II.
Nitiss JL; Liu YX; Harbury P; Jannatipour M; Wasserman R; Wang JC
Cancer Res; 1992 Aug; 52(16):4467-72. PubMed ID: 1322791
[TBL] [Abstract][Full Text] [Related]
36. Role of proliferation in determining sensitivity to topoisomerase II-active chemotherapy agents.
Sullivan DM; Chow KC; Glisson BS; Ross WE
NCI Monogr; 1987; (4):73-8. PubMed ID: 2819735
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and antitumour activities of quinolone antineoplastic agents.
Chu DT; Hallas R; Clement JJ; Alder J; McDonald E; Plattner JJ
Drugs Exp Clin Res; 1992; 18(7):275-82. PubMed ID: 1338309
[TBL] [Abstract][Full Text] [Related]
38. In vivo and in vitro stimulation by antitumor drugs of the topoisomerase II-induced cleavage sites in c-myc proto-oncogene.
Riou JF; Vilarem MJ; Larsen CJ; Multon E; Riou GF
NCI Monogr; 1987; (4):41-7. PubMed ID: 2819730
[TBL] [Abstract][Full Text] [Related]
39. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F
Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987
[TBL] [Abstract][Full Text] [Related]
40. A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine.
Elsea SH; Hsiung Y; Nitiss JL; Osheroff N
J Biol Chem; 1995 Jan; 270(4):1913-20. PubMed ID: 7829529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
